RxDoctor Payments Data

John Clancy, DO

Internal Medicine · Vista, CANPI 1962506238

Payments from drug & device makers

$264in general payments, 2019–2025

Across 15 payments — averaging $17.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$56
  • Novo Nordisk$49
  • Pfizer$42
  • Sanofi Pasteur Inc.$22
  • Merck$18
  • Linus Health, Inc.$18
  • plus $58 from 4 others

What the payments were for

  • Food & beverage$264100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen2$56
Novo Nordisk3$49
Pfizer2$42
Sanofi Pasteur Inc.2$22
Merck1$18
Linus Health, Inc.1$18
Assertio Therapeutics, Inc.1$16
Novartis1$16
Boston Scientific1$14
AstraZeneca1$11

How this compares

$264 in reported general payments places this provider in the 55th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$389,104
Medicare patients
250
Services billed
5,568

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin39$60,468
EliquisApixaban37$57,880
OzempicSemaglutide33$51,379
XareltoRivaroxaban15$25,036
TrulicityDulaglutide12$23,133
JanuviaSitagliptin Phosphate15$21,790
FarxigaDapagliflozin Propanediol11$14,751
MounjaroTirzepatide11$12,519
RybelsusSemaglutide11$9,779
Albuterol Sulfate HfaAlbuterol Sulfate107$5,695
BelsomraSuvorexant11$4,901
Wixela InhubFluticasone Propion/Salmeterol17$4,506
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen86$2,933
Atorvastatin Calcium247$2,757
Levothyroxine Sodium168$2,412

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$49$61,15844 claims
PfizerEliquis$42$57,88037 claims
MerckJanuvia, Belsomra$18$26,69126 claims
AstraZenecaFarxiga$11$14,75111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Vista

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →